Breaking Finance News

Boston Scientific (NYSE:BSX) target bumped up to $28.00, released a ratings update today by Goldman Sachs

Yesterday Boston Scientific (NYSE:BSX) traded 0.57% higher at $26.42. The company’s 50-day moving average is $25.33 and its 200-day moving average is $23.55. The last closing price is up 12.81% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 5,413,126 shares of the stock were exchanged, down from an average trading volume of 7,485,940

Boston Scientific (NYSE:BSX) had its target bumped up to $28.00 by Goldman Sachs in a report issued 5/16/2017. The updated stock price target implies a potential upside of 0.06% from the company's last closing price.

Previously on 5/01/2017, Cowen reported on Boston Scientific (NYSE:BSX) raised the target price from $29.00 to $31.00. At the time, this indicated a possible upside of 0.18%.

See Chart Below

Boston Scientific (NYSE:BSX)

Boston Scientific has a 52 week low of $19.67 and a 52 week high of $26.76 with a P/E ratio of 85.16 The company’s market cap is currently $0.

In addition to Goldman Sachs reporting its target price, a total of 26 brokers have issued a report on the stock. The consensus target price is $24.46 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Boston Scientific (NYSE:BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *